Experimental antibody for severe COVID-19 falls short as trial ends early
NCT ID NCT04644185
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This study tested an experimental antibody called SCTA01 in hospitalized adults with severe COVID-19. The goal was to see if it could speed up recovery compared to a placebo. The trial was stopped early after enrolling 102 participants, so the results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SCT study site
Somers Point, New Jersey, 08244, United States
-
SCT study site
Buenos Aires, Argentina
-
SCT study site
Uberlândia, Brazil
-
SCT study site
Talca, Chile
-
SCT study site
Rionegro, Colombia
-
SCT study site
Monterrey, Mexico
-
SCT study site
Lima, Peru
Conditions
Explore the condition pages connected to this study.